{"id":"https://openalex.org/W4290803731","doi":"https://doi.org/10.1158/2767-9764.crc-21-0095","title":"The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand\u2013dependent Cancer Models","display_name":"The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand\u2013dependent Cancer Models","publication_year":2022,"publication_date":"2022-08-11","ids":{"openalex":"https://openalex.org/W4290803731","doi":"https://doi.org/10.1158/2767-9764.crc-21-0095","pmid":"https://pubmed.ncbi.nlm.nih.gov/36922934","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/10010340"},"language":"en","primary_location":{"id":"doi:10.1158/2767-9764.crc-21-0095","doi":"https://doi.org/10.1158/2767-9764.crc-21-0095","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-21-0095","pdf_url":null,"source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/2767-9764.crc-21-0095","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108257450","display_name":"Caroline Phillips","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162142","display_name":"Redx Pharma (United Kingdom)","ror":"https://ror.org/04wysdg63","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210162142"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Caroline Phillips","raw_affiliation_strings":["1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","institution_ids":["https://openalex.org/I4210162142"]},{"raw_affiliation_string":"Cheshire, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082399428","display_name":"Inder Bhamra","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162142","display_name":"Redx Pharma (United Kingdom)","ror":"https://ror.org/04wysdg63","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210162142"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Inder Bhamra","raw_affiliation_strings":["1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","institution_ids":["https://openalex.org/I4210162142"]},{"raw_affiliation_string":"Cheshire, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063198530","display_name":"Catherine Eagle","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162142","display_name":"Redx Pharma (United Kingdom)","ror":"https://ror.org/04wysdg63","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210162142"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Catherine Eagle","raw_affiliation_strings":["1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","institution_ids":["https://openalex.org/I4210162142"]},{"raw_affiliation_string":"Cheshire, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060597851","display_name":"Eimear Flanagan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162142","display_name":"Redx Pharma (United Kingdom)","ror":"https://ror.org/04wysdg63","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210162142"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Eimear Flanagan","raw_affiliation_strings":["1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","institution_ids":["https://openalex.org/I4210162142"]},{"raw_affiliation_string":"Cheshire, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081842675","display_name":"Richard E Armer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162142","display_name":"Redx Pharma (United Kingdom)","ror":"https://ror.org/04wysdg63","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210162142"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Richard Armer","raw_affiliation_strings":["1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","institution_ids":["https://openalex.org/I4210162142"]},{"raw_affiliation_string":"Cheshire, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091755518","display_name":"Clifford D. Jones","orcid":"https://orcid.org/0000-0002-9953-4824","observed_orcids":["https://orcid.org/0000-0002-9953-4824"]},"institutions":[{"id":"https://openalex.org/I4210162142","display_name":"Redx Pharma (United Kingdom)","ror":"https://ror.org/04wysdg63","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210162142"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Clifford D. Jones","raw_affiliation_strings":["1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","Cheshire, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-9953-4824","affiliations":[{"raw_affiliation_string":"1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","institution_ids":["https://openalex.org/I4210162142"]},{"raw_affiliation_string":"Cheshire, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055499083","display_name":"Matilda J. Bingham","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210152657","display_name":"Concept Life Sciences (United Kingdom)","ror":"https://ror.org/03zm7w502","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210152657"]},{"id":"https://openalex.org/I4210162142","display_name":"Redx Pharma (United Kingdom)","ror":"https://ror.org/04wysdg63","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210162142"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Matilda Bingham","raw_affiliation_strings":["1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","2Concept Life Sciences Ltd, Manchester, United Kingdom","Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","institution_ids":["https://openalex.org/I4210162142"]},{"raw_affiliation_string":"2Concept Life Sciences Ltd, Manchester, United Kingdom","institution_ids":["https://openalex.org/I4210152657"]},{"raw_affiliation_string":"Cheshire, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067029431","display_name":"Peter J. Calcraft","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]},{"id":"https://openalex.org/I4210162142","display_name":"Redx Pharma (United Kingdom)","ror":"https://ror.org/04wysdg63","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210162142"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Peter Calcraft","raw_affiliation_strings":["1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","3Analytical Development, Flu-BPD, AstraZeneca PLC, Manchester, United Kingdom","Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","institution_ids":["https://openalex.org/I4210162142"]},{"raw_affiliation_string":"3Analytical Development, Flu-BPD, AstraZeneca PLC, Manchester, United Kingdom","institution_ids":["https://openalex.org/I105036370"]},{"raw_affiliation_string":"Cheshire, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045023434","display_name":"Alicia Edmenson Cook","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]},{"id":"https://openalex.org/I4210162142","display_name":"Redx Pharma (United Kingdom)","ror":"https://ror.org/04wysdg63","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210162142"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alicia Edmenson Cook","raw_affiliation_strings":["1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","4Oncology Cell Therapy, GlaxoSmithKline PLC, London, United Kingdom","Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","institution_ids":["https://openalex.org/I4210162142"]},{"raw_affiliation_string":"4Oncology Cell Therapy, GlaxoSmithKline PLC, London, United Kingdom","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"Cheshire, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Ben Thompson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162142","display_name":"Redx Pharma (United Kingdom)","ror":"https://ror.org/04wysdg63","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210162142"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ben Thompson","raw_affiliation_strings":["1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","5In Vitro, RxCelerate Ltd, Cambridge, United Kingdom","Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","institution_ids":["https://openalex.org/I4210162142"]},{"raw_affiliation_string":"5In Vitro, RxCelerate Ltd, Cambridge, United Kingdom","institution_ids":[]},{"raw_affiliation_string":"Cheshire, United Kingdom","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5003246050","display_name":"Simon A. Woodcock","orcid":"https://orcid.org/0000-0001-7363-757X","observed_orcids":["https://orcid.org/0000-0001-7363-757X"]},"institutions":[{"id":"https://openalex.org/I4210162142","display_name":"Redx Pharma (United Kingdom)","ror":"https://ror.org/04wysdg63","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210162142"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Simon A. Woodcock","raw_affiliation_strings":["1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","Cheshire, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0001-7363-757X","affiliations":[{"raw_affiliation_string":"1Redx Oncology Ltd, Redx Pharma PLC; Cheshire, United Kingdom","institution_ids":["https://openalex.org/I4210162142"]},{"raw_affiliation_string":"Cheshire, United Kingdom","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5003246050"],"corresponding_institution_ids":["https://openalex.org/I4210162142"],"apc_list":{"value":2550,"currency":"USD","value_usd":2550},"apc_paid":{"value":2550,"currency":"USD","value_usd":2550},"fwci":1.9853,"has_fulltext":false,"cited_by_count":40,"citation_normalized_percentile":{"value":0.88041108,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"2","issue":"9","first_page":"914","last_page":"928"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10929","display_name":"Wnt/\u03b2-catenin signaling in development and cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10929","display_name":"Wnt/\u03b2-catenin signaling in development and cancer","score":1.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12009","display_name":"Hedgehog Signaling Pathway Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/wnt-signaling-inhibition","display_name":"Wnt signaling inhibition","score":0.7620000243186951},{"id":"https://openalex.org/keywords/porcupines","display_name":"porcupines","score":0.7919999957084656},{"id":"https://openalex.org/keywords/o-acyltransferase","display_name":"O-acyltransferase","score":0.8100000023841858},{"id":"https://openalex.org/keywords/wnt-ligand-secretion","display_name":"Wnt ligand secretion","score":0.8080000281333923},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.8889999985694885},{"id":"https://openalex.org/keywords/pancreatic-cancer","display_name":"pancreatic cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/rnf43-mutation","display_name":"RNF43 mutation","score":0.9330000281333923},{"id":"https://openalex.org/keywords/tumor-immune-evasion","display_name":"tumor immune evasion","score":0.9200000166893005},{"id":"https://openalex.org/keywords/myeloid-derived-suppressor-cells","display_name":"myeloid-derived suppressor cells","score":0.9649999737739563},{"id":"https://openalex.org/keywords/tumor-metabolism","display_name":"cancer metabolism","score":0.628000020980835},{"id":"https://openalex.org/keywords/glucose-uptake","display_name":"glucose uptake","score":0.4699999988079071}],"concepts":[{"id":"https://openalex.org/C137620995","wikidata":"https://www.wikidata.org/wiki/Q155769","display_name":"Wnt signaling pathway","level":3,"score":0.7959598302841187},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6195371150970459},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5289779901504517},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.5092026591300964},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.49883341789245605},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.32451295852661133},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.26275020837783813},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.25821638107299805},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.2566085457801819},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007963","descriptor_name":"Leukocytes, Mononuclear","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008024","descriptor_name":"Ligands","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015179","descriptor_name":"Colorectal Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057131","descriptor_name":"Immune Evasion","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D060449","descriptor_name":"Wnt Signaling Pathway","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/2767-9764.crc-21-0095","doi":"https://doi.org/10.1158/2767-9764.crc-21-0095","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-21-0095","pdf_url":null,"source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10010340","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10010340","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Res Commun","raw_type":"Text"},{"id":"pmid:36922934","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36922934","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer research communications","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1158/2767-9764.crc-21-0095","doi":"https://doi.org/10.1158/2767-9764.crc-21-0095","is_oa":true,"landing_page_url":"https://doi.org/10.1158/2767-9764.crc-21-0095","pdf_url":null,"source":{"id":"https://openalex.org/S4210217028","display_name":"Cancer Research Communications","issn_l":"2767-9764","issn":["2767-9764"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research Communications","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9789000153541565}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":54,"referenced_works":["https://openalex.org/W808646684","https://openalex.org/W1586218645","https://openalex.org/W1655178001","https://openalex.org/W1900557155","https://openalex.org/W1994029539","https://openalex.org/W1995773697","https://openalex.org/W2006419043","https://openalex.org/W2017828716","https://openalex.org/W2022495797","https://openalex.org/W2031868265","https://openalex.org/W2041812469","https://openalex.org/W2063188304","https://openalex.org/W2063495860","https://openalex.org/W2067826589","https://openalex.org/W2078060536","https://openalex.org/W2083457841","https://openalex.org/W2090789702","https://openalex.org/W2106541980","https://openalex.org/W2132659357","https://openalex.org/W2135372466","https://openalex.org/W2142300779","https://openalex.org/W2157216791","https://openalex.org/W2165087323","https://openalex.org/W2166178545","https://openalex.org/W2168623286","https://openalex.org/W2207864075","https://openalex.org/W2308877979","https://openalex.org/W2323180357","https://openalex.org/W2558715006","https://openalex.org/W2655262992","https://openalex.org/W2748338775","https://openalex.org/W2756896022","https://openalex.org/W2771031544","https://openalex.org/W2775913442","https://openalex.org/W2783494975","https://openalex.org/W2801923172","https://openalex.org/W2803586435","https://openalex.org/W2886229758","https://openalex.org/W2888597034","https://openalex.org/W2891828924","https://openalex.org/W2894924427","https://openalex.org/W2901522674","https://openalex.org/W2909312563","https://openalex.org/W2952001837","https://openalex.org/W2976026968","https://openalex.org/W3082629256","https://openalex.org/W3088005314","https://openalex.org/W3100750497","https://openalex.org/W3106403851","https://openalex.org/W3158215128","https://openalex.org/W3159588552","https://openalex.org/W3202221618","https://openalex.org/W4221016108","https://openalex.org/W6756486766"],"related_works":["https://openalex.org/W4240636458","https://openalex.org/W2956140870","https://openalex.org/W3178579248","https://openalex.org/W2889731004","https://openalex.org/W3202221618","https://openalex.org/W4308383995","https://openalex.org/W2885208058","https://openalex.org/W4240262927","https://openalex.org/W4282971406","https://openalex.org/W4281858602"],"abstract_inverted_index":{"Wnt":[0,12,48,124,137,172,259,298,313],"signaling":[1,13],"is":[2,14,316],"implicated":[3],"in":[4,64,70,81,89,92,101,113,136,157,185,188,290,311,320],"the":[5,29,41,229,243,274,279],"etiology":[6],"of":[7,23,33,40,177,232,247,297,305],"gastrointestinal":[8,264,300],"tract":[9],"cancers.":[10,301],"Targeting":[11],"challenging":[15],"due":[16],"to":[17,217,281],"on-target":[18],"toxicity":[19],"concerns":[20],"and":[21,31,37,54,56,66,76,85,91,105,112,128,131,143,150,161,187,193,209,286,307],"lack":[22],"druggable":[24],"pathway":[25,129,260],"components.":[26],"We":[27],"describe":[28],"discovery":[30],"characterization":[32],"RXC004,":[34,306],"a":[35,119,168,291],"potent":[36,133],"selective":[38],"inhibitor":[39],"membrane-bound":[42],"o-acyl":[43],"transferase":[44],"Porcupine,":[45],"essential":[46],"for":[47],"ligand":[49,125],"secretion.":[50],"Absorption,":[51],"distribution,":[52],"metabolism,":[53],"excretion":[55],"safety":[57],"pharmacology":[58],"studies":[59],"were":[60,79,99,155,183],"conducted":[61],"with":[62,167,211,236],"RXC004":[63,72,94,117,178,196,227,276],"vitro,":[65],"pharmacokinetic":[67,121],"exposure":[68],"assessed":[69,100,319],"vivo.":[71,93],"effects":[73,95,135,176,231],"on":[74,96,179],"proliferation":[75],"tumor":[77,148,180,199,284,287],"metabolism":[78,182],"explored":[80],"genetically":[82,292],"defined":[83],"colorectal":[84,142],"pancreatic":[86,144],"cancer":[87,152],"models":[88],"vitro":[90,186],"immune":[97,103,107,288],"evasion":[98,289],"B16F10":[102,207],"\u201ccold\u201d":[104],"CT26":[106,224],"\u201chot\u201d":[108],"murine":[109],"syngeneic":[110],"models,":[111,166],"human":[114,237],"cell":[115,145,153,181,213,221],"cocultures.":[116],"showed":[118],"promising":[120],"profile,":[122],"inhibited":[123],"palmitoylation,":[126],"secretion,":[127],"activation,":[130],"demonstrated":[132,278],"antiproliferative":[134],"ligand\u2013dependent":[138,299,314],"(RNF43-mutant":[139],"or":[140],"RSPO3-fusion)":[141],"lines.":[146],"Reduced":[147],"growth":[149,285],"increased":[151],"differentiation":[154],"observed":[156],"SNU-1411":[158],"(RSPO3-fusion),":[159],"AsPC1":[160],"HPAF-II":[162,233],"(both":[163],"RNF43-mutant)":[164],"xenograft":[165],"therapeutic":[169],"window":[170],"versus":[171],"homeostatic":[173],"functions.":[174],"Additional":[175],"confirmed":[184],"vivo":[189],"by":[190],"glucose":[191],"uptake":[192],"18fluorodeoxyglucose-PET,":[194],"respectively.":[195],"stimulated":[197],"host":[198],"immunity;":[200],"reducing":[201],"resident":[202],"myeloid-derived":[203],"suppressor":[204],"cells":[205,234],"within":[206,223],"tumors":[208],"synergizing":[210],"anti-programmed":[212],"death":[214],"protein-1":[215],"(PD-1)":[216],"increase":[218],"CD8+/regulatory":[219],"T":[220],"ratios":[222],"tumors.":[225],"Moreover,":[226],"reversed":[228],"immunosuppressive":[230],"cocultured":[235],"peripheral":[238],"blood":[239],"mononuclear":[240],"cells,":[241],"confirming":[242],"multiple":[244],"anticancer":[245],"mechanisms":[246],"this":[248],"compound,":[249],"which":[250],"has":[251,277],"progressed":[252],"into":[253],"phase":[254],"II":[255],"clinical":[256,303],"trials.":[257,322],"Significance:":[258],"dysregulation":[261],"drives":[262],"many":[263],"cancers;":[265],"however,":[266],"there":[267],"are":[268],"no":[269],"approved":[270],"therapies":[271],"that":[272],"target":[273],"pathway.":[275],"potential":[280],"block":[282],"both":[283],"defined,":[293],"clinically":[294],"actionable":[295],"subpopulation":[296],"The":[302],"utility":[304],"other":[308],"Porcupine":[309],"inhibitors,":[310],"such":[312],"cancers":[315],"currently":[317],"being":[318],"patient":[321]},"counts_by_year":[{"year":2026,"cited_by_count":13},{"year":2025,"cited_by_count":13},{"year":2024,"cited_by_count":11},{"year":2023,"cited_by_count":3}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2022-08-12T00:00:00"}